摘要
神经内分泌肿瘤肝转移（NETLM）临床少见、预后差，不可切除的NETLM更为临床治疗的难点。钇^90微球栓塞治疗不可切除的NETLM安全有效，中位肿瘤控制率为87．1％（64．7％～100％），患者中位生存期为34．4个月，1、2、3年中位生存率分别为79．8％（63％～100％）、62％（57％～62．5％）、45．5％（45％～46％）。虽然钇^90微球栓塞治疗不可切除的NETLM取得了一定的疗效，但仍需进一步验证其有效性及安全性。
Neuroendocrine tumor liver metastases （NETLM） is a uncommon advanced tumor disease. Patients with unresectahle NETLM have a poor outcome. The management of unresectable NETLM is a clinical dilemma. However, Yttrium-90 radioembolization is a safe and effective treatment for NETLM patients. The median disease control rate is 87. 1% （64. 7% - 100% ）; the median overall survival time is 34.4 months; and the median overall survival rate of 1, 2, and 3 years are 79.8% （63% -100%）, 62% （57% -62.5%）, 45.5% （45% - 46% ） , respectively. Although there is good result of Yttrium-90 radioembolization in treatment of unresectable NETLM, the safety and effectiveness should be further verified.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2016年第5期355-357,共3页
Chinese Journal of Hepatobiliary Surgery
